The CBX7 antibody is a research tool targeting the Chromobox homolog 7 (CBX7) protein, a member of the Polycomb Repressive Complex 1 (PRC1) involved in epigenetic gene regulation. CBX7 binds to trimethylated lysine 27 on histone H3 (H3K27me3), a chromatin modification mark associated with transcriptional repression. It plays critical roles in maintaining cellular identity, stem cell pluripotency, and cell cycle control by silencing genes through chromatin compaction. Dysregulation of CBX7 has been implicated in cancer, though its role remains controversial—it exhibits both oncogenic and tumor-suppressive functions depending on tissue context. For instance, CBX7 is overexpressed in colorectal and ovarian cancers, promoting proliferation, while its downregulation correlates with poor prognosis in thyroid and pancreatic cancers. Researchers use CBX7 antibodies in techniques like Western blotting, immunohistochemistry, and ChIP-seq to study its expression patterns, interactions, and regulatory mechanisms. These studies aim to clarify CBX7’s dual roles in tumorigenesis and explore its potential as a therapeutic target. The antibody’s specificity and validation across applications make it essential for advancing understanding of PRC1-mediated epigenetic processes and their implications in disease.